Unmet need in heavily pre-treated patients with HR+/HER2-metastatic breast cancer (mBC) in the US: A ConcertAI analysis

被引：1
|
作者：
Waks, A. G. [1 ]
Gharaibeh, M. [2 ]
Sjekloca, N. [3 ]
Poluparthi, N. [2 ]
Shah, A. [2 ]
Bergamaco, E. [4 ]
MacCannell, T. [2 ]
Leung, G. [5 ]
Ntalla, I. [6 ]
Oko-osi, H. [2 ]
Tolaney, S. M. [1 ]
机构：
[1] Dana Farber Canc Inst, Med Oncol, Boston, MA USA
[2] Gilead Sci Inc, Dept Hlth Econ & Outcomes Res, Foster City, CA USA
[3] Gilead Sci Europe Ltd, Dept Med Affairs, Stockley Pk, CA USA
[4] Gilead Sci Inc, Dept Med Affairs, Foster City, CA USA
[5] Gilead Sci Inc, Dept Real World Evidence, Foster City, CA USA
[6] Gilead Sci Europe Ltd, Dept Real World Evidence, Stockley Pk, CA USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.292
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
253P
引用
收藏
页码：S653 / S653
页数：1
相关论文
共 50 条
  • [41] Evolution of prescribing trends for HR+/HER2-metastatic breast cancer (mBC) in a post-CDK4/6i world
    Feinberg, Bruce
    Dokubo, Igoni
    Wojtynek, Jeff
    Kish, Jonathan
    CANCER RESEARCH, 2021, 81 (04)
  • [42] Real-world predictors of first-line treatment and descriptive outcomes in HR+/HER2-metastatic breast cancer patients in the US
    Downer, M. K.
    Jhaveri, Komal
    Bardia, Aditya
    Loi, Sherene
    Kent, Matthew
    Luhn, Patricia
    Humke, Eric W.
    CANCER RESEARCH, 2020, 80 (04)
  • [43] Identifying drivers of first-line HR+/HER2-metastatic breast cancer treatment choices
    Brufsky, Adam
    Maculaitis, Martine C.
    Kopenhafer, Lewis
    Olsen, Patrick
    Kurosky, Samantha K.
    Arruda, Lillian Shahied
    Heck, Wendy
    Cha-Silva, Ashley S.
    FUTURE ONCOLOGY, 2024,
  • [44] Identifying Drivers of First-Line HR+/HER2-Metastatic Breast Cancer Treatment Choices
    Brufsky, Adam M.
    Maculaitis, Martine C.
    Kopenhafer, Lewis
    Olsen, Patrick
    Cha, Ashley S.
    Arruda, Lillian Shahied
    Heck, Wendy
    Kurosky, Samantha K.
    CANCER RESEARCH, 2023, 83 (05)
  • [45] Patient and treatment characteristics in HR+/HER2-metastatic breast cancer in a real-life setting
    Karadurmus, Nuri
    Sendur, Mehmet Ali Nahit
    Cil, Timucin
    Oksuzoglu, Omur Berna Cakmak
    Arslan, Cagatay
    Harputluoglu, Hakan
    Goksu, Sema Sezgin
    Ozturk, Banu
    MevludeInanc
    Cubukcu, Erdem
    Demirci, Umut
    Erdem, Dilek
    Cihan, Sener
    Tural, Deniz
    Dumludag, Aysegul
    Yilmaz, Funda
    Avsar, Esin
    Sonusen, Sermin Dinc
    Ozturk, Ozge Fulya
    Aver, Birkan
    Kaplan, Muhammet Ali
    CANCER RESEARCH, 2023, 83 (05)
  • [46] The association between age, toxicity and outcomes of abemaciclib treatment in HR+/HER2-metastatic breast cancer
    Ovcaricek, Tanja
    Matos, Erika
    Borstnar, Simona
    Ribnikar, Domen
    Kuhar, Cvetka Grasic
    Cankar, Kaja
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Treatment patterns and characteristics of postmenopausal women with HR+/HER2-metastatic breast cancer receiving everolimus
    Vekeman, Francis
    Hao, Yanni
    Cheng, Wendy Y.
    Fortier, Jonathan
    Robitaille, Marie-Noelle
    Duh, Mei Sheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 114 - 115
  • [48] Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2-Metastatic Breast Cancer
    Dalal, Anand A.
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Gauthier, Genevieve
    Small, Tania
    Niravath, Polly
    ADVANCES IN THERAPY, 2018, 35 (06) : 768 - 778
  • [49] Lapatinib with trastuzumab for heavily treated HER2-positive metastatic breast cancer (mBC).
    Sotelo, Miguel J.
    Manso, Luis
    Garcia Saenz, Jose Angel
    Ciruelos, Eva M.
    Moreno, Fernando
    Mendiola, Cesar
    Callata, Hector
    Ghanem, Ismael
    Cabezas, Santiago
    Gonzalez-Larriba, Jose-Luis
    Diaz Rubio, Eduardo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer
    Chen, Pei-Hsin
    Yeh, Dah-Cherng
    Tung, Heng-Hsin
    Lin, Chin-Yao
    MEDICINE, 2021, 100 (47)
12345